Roth MKM downgraded Cyclacel Pharmaceuticals (CYCC) to Neutral from Buy.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYCC:
- Cyclacel reports clinical data from Phase 2 study of oral fadraciclib
- Biotech Alert: Searches spiking for these stocks today
- Cyclacel Pharmaceuticals files to sell common stock, warrants, no amount given
- Cyclacel completes enrollment in Cohort 8 of Phase 2 study of fadraciclib
- Cyclacel Pharmaceuticals confirms filing of appeal to Nasdaq delisting letter